Compare Corsair Gaming Inc (CRSR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs ResMed Inc. — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 22.5× Corsair Gaming Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and ResMed Inc. for 51 Days on average.
| CRSR | RMD | |
|---|---|---|
Market Cap | $1.42B | $31.89B |
Volume | 1,160,938 | 618,314 |
Sector | Technology | Health |
52-Week High | $14.35 | $275.96 |
52-Week Low | $4.58 | $182.82 |
Typical Hold Time | 25 Days | 51 Days |
Enterprise Value | $1.41B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSR trades at $13.09, down 3.68% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q2 2026 EPS of $0.23, beating estimates of $0.07, and raised full-year guidance. Revenue for 2025 was $1.47B, with a net income margin of 2.53% in 2026 projections. Analyst consensus is a $12.40 price target with a mix of Buy (36%) and Hold (64%) ratings. Recent news includes product launches like the VOXARA microphone and strategic acquisitions.
Outlook is cautiously optimistic due to strong earnings performance and new product initiatives, but risks include competitive pressures in gaming hardware and volatile cash flow trends. The stock's valuation at a P/E of 42.23 may limit near-term upside unless profit growth accelerates. Institutional interest is positive, with Canada Pension Plan adding a position in Q3 2026.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
